DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast - 2023" drug pipelines to their offering.
This report provides an overview of the disease and market size of the CMV for the global market, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for 2013 - 2023.
It also includes global historical and forecasted epidemiological data for the CMV Prevalent, Diagnosed and Treatable Cases, CMV Patients among Transplants, Infants Patients at High Risk of CMV and HIV Patients at High Risk of CMVfrom 2013 - 2023. According to experts, the Global Diagnosed cases for Cytomegalovirus (CMV) Infection are expected to increase at a CAGR of 0.047% to 172,864 cases in 2023.
Cytomegalovirus (CMV) infection is caused by Cytomegalovirus (CMV), a member of the herpes virus family. Upon initial infection, CMV infects the epithelial cells of the salivary gland, resulting in a persistent infection and viral shedding. Person can be infected with CMV at any point of time in life and is not easily diagnosed as no symptoms are shown.
As per our estimation, the global market size of Cytomegalovirus (CMV) infection shall reach to USD 1,210.4 Million by the end of 2023. The market size for Prophylaxis is expected to grow at a CAGR 6.57% from 2013 - 2023, while the sales for the therapeutic shall increase at a CAGR of 3.44% from the 2013 - 2023.
- Valcyte (Valganciclovir hydrochloride)
- FOSCAVIR (foscarnet sodium)
- CytoGam (Cytomegalovirus Immune Globulin Intravenous-Human)
- CytoTect CP
- Valtrex (Valacyclovir hydrochloride)
Emerging Products Analysis
- Cytovir CMV: Cell Medica Ltd.
- CytoTect CP 70: Biotest AG
- Letermovir: Merck & Co.
- Brincidofovir: Chimerix Inc.
- ASP0113: Astellas Pharma Global Development, Inc.
- Human Cytomegalovirus Immune Globulin: CSL Behring
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/d7h2wj/cytomegalovirus